Recent Company News

• 01:05 AM ET May 12, 2025
  

  Addex partner Indivior advances GABAB positive Allosteric modulator program successfully through ind enabling studies (CHF 0.06, 0.00)

• 01:30 AM ET Apr 30, 2025
  

  Addex Therapeutics enters option- and collaboration agreement with Sinntaxis AB for an exclusive license to intellectual property covering the use of metabotropic glutamate receptor subtype 5 inhibitors for the treatment of brain injury recovery

• 04:19 AM ET Sep 30, 2024
  

  StreetAccount Summary - Trading higher/lower: EU mid-morning

• 01:13 AM ET Apr 25, 2025
  

  Addex Therapeutics reports FY net income from cont. ops (CHF4.9M) (CHF 0.05, 0.00)

• 01:08 AM ET Apr 17, 2025
  

  Addex Therapeutics announces Janssen Pharmaceuticals has returned all development and commercialization rights to ADX71149 (JNJ-40411813) and the partnership between the two companies has been terminated (CHF 0.05, 0.00)

• 01:07 AM ET Nov 22, 2024
  

  Addex Therapeutics reports final Q3 earnings: EPS (CHF0.02) vs FactSet (CHF0.01) [1 est] (CHF 0.06, 0.00)

• 01:04 AM ET Nov 11, 2024
  

  Addex Therapeutics reports preliminary Q3 net income (CHF1.5M) vs FactSet (CHF0.9M) [1 est] (CHF 0.09, 0.00)

• 01:05 AM ET Sep 30, 2024
  

  Addex Therapeutics reports Q2 net income from cont. ops. (CHF1.5M) (CHF 0.07, 0.00)